Start Submission Become a Reviewer

Reading: Clinical Application of WHF-MOGE(S) Classification for Hypertrophic Cardiomyopathy

Download

A- A+
Alt. Display

Original Research

Clinical Application of WHF-MOGE(S) Classification for Hypertrophic Cardiomyopathy

Authors:

Anushree Agarwal,

Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, US
X close

Rayan Yousefzai,

Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, US
X close

M. Fuad Jan,

Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, US
X close

Chi Cho,

Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, US
X close

Kambiz Shetabi,

Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, US
X close

Michelle Bush,

Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, US
X close

Bijoy K. Khandheria,

Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, US
X close

Timothy E. Paterick,

Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, US
X close

Shannon Treiber,

Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, US
X close

Jasbir Sra,

Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, US
X close

Suhail Allaqaband,

Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, US
X close

Tanvir Bajwa,

Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, US
X close

A. Jamil Tajik

Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, US
X close

Abstract

Background: Recently, a new MOGE(S) (Morphofunctional, Organ involvement, Genetics, Etiology of details of the genetic disease or underlying cause, and functional Status) genotype to phenotype nosology system for classification of cardiomyopathies was proposed, but its clinical use has not been described.

Objectives: This study presents the comprehensive geno-phenotypic evaluation of hypertrophic cardiomyopathy (HCM) patients by employing the newly proposed World Heart Federation classification of cardiomyopathies — the MOGE(S) classification.

Methods: From January 2011 to March 2014, 254 patients were evaluated (190 probands and 64 family members). Of those, 181 were HCM phenotype-positive probands, and 54.7% were male patients. Mean maximal left ventricular thickness was 2.2 ± 0.6 cm, with >2.5 cm thickness seen in 21.5% of patients. Obstructive HCM was present in 66.3% of patients, with an average peak gradient of 57.1 ± 47.2. Detailed clinical, imaging, and follow-up data were analyzed. Gene testing was performed in 129 patients (67.9%), and they were categorized into gene-positive (MHOHGADEG+) and gene-negative (MHOHGADEG–) groups based on the MOGE(S) classification.

Results: MHOHGADEG+ patients were younger at time of diagnosis, more likely to be female, more likely to have ventricular tachycardia and a family history of HCM or sudden death, had lower peak gradients, and were more likely to have sudden death risk factors.

Conclusions: In addition to employing genotype-to-phenotype nosology to describe HCM, we propose a modification to the current MOGE(S) classification for HCM based on the presence or absence of obstruction and location of hypertrophy within the morphology.

Highlights

  • We present a most contemporary regional hypertrophic cardiomyopathy center experience.
  • We propose a modification to the MOGE(S) (Morphofunctional, Organ involvement, Genetics, Etiology of details of the genetic disease or underlying cause, and functional Status) classification for hypertrophic cardiomyopathy.
  • MOGE(S) classification provides insight about clinical course and facilitates communication.
How to Cite: Agarwal A, Yousefzai R, Jan MF, Cho C, Shetabi K, Bush M, et al.. Clinical Application of WHF-MOGE(S) Classification for Hypertrophic Cardiomyopathy. Global Heart. 2015;10(3):209–19. DOI: http://doi.org/10.1016/j.gheart.2015.01.001
7
Views
10
Downloads
7
Citations
Published on 01 Sep 2015.
Peer Reviewed

Downloads

  • PDF (EN)

    comments powered by Disqus